Logo

We’re making history, one milestone at a time

Follow our progress as we work toward our vision of improving outcomes for people with cancer.

Recent News

October 14, 2021
Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies

September 15, 2020
Tizona Appoints Christine O’Brien as Chief Executive Officer

July 21, 2020
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million.  

June 25, 2020
Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers 

February 19, 2020
Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference

View More News

Media Contact

media@tizonatx.com

  • Home
  • About
    • Our Vision
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
    • Partners
    • IRS Form 8937
  • Our Science
    • Pipeline
    • Key Programs
  • News
    • Press Releases
  • Team Tizona
    • Our Values
    • Culture and Benefits
    • Job Opportunities
      • EA/ Program Coordinator
  • Contact
© 2023 Tizona Therapeutics, Inc. All rights reserved.Website Design: Hane Chow, Inc.